Blake Borgeson - Jan 3, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jan 3, 2022
Transactions value $
-$173,528
Form type
4
Date filed
1/5/2022, 07:39 PM
Previous filing
Dec 23, 2021
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +555 +0.01% $0.00 7.66M Jan 3, 2022 Direct F1
transaction RXRX Class A Common Stock Sale -$174K -9.63K -0.13% $18.03 7.65M Jan 4, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.00 to $18.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.